1100 13th Street, NW, Suite 750Washington, DC 20005202.887.6400Customer Service: 800.544.0155
All Contents © 2019The Kiplinger Washington Editors
Biotech stocks typically are considered one of Wall Street’s more aggressive sources of growth. These companies spend years and gobs of money to create breakthrough biological treatments and diagnostic...
Seth Klarman was prescient in recognizing that the genomics revolution would supercharge the biotech industry.
Investors looking for a high income stream often balk at closed-end funds (CEFs) because of their higher fees. CEFs’ average annual fees sit at 1.09% (or $109 for every $10,000 invested),...
More Investing News »